About 38% of rads surveyed said they had defended against at least one lawsuit, with such specialists at a higher risk than others in internal medicine.
Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.
The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.
U.S. healthcare is in the throes of an affordability crisis. The good news is that healthcare leaders have all the evidence, tools and expertise needed to keep the predicament from becoming a plight. Can they marshal the will to wield those weapons toward that end?
The new Class I recall, which includes more than 1.4 million devices, is related to an issue first announced back in 2024. Updating the software should address the issue going forward, though some patients may still require an early replacement.
About 38% of rads surveyed said they had defended against at least one lawsuit, with such specialists at a higher risk than others in internal medicine.
Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.
